Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
50 participants
INTERVENTIONAL
2025-03-03
2026-08-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluatıon of the Effect of Pulpotomy Treatments Wıth Dıfferent Bıomaterıals on Postoperatıve Paın In Permanent Molars
NCT06784622
The Effect of Different Treatment Methods on the Apical Closure and Treatment Success in Permanent First Molars
NCT06575062
Assessment of Vital Pulp Therapy in Permanent Molars
NCT03410134
Cytokines as Diagnostic Markers of Pulpal Inflammation and Their Impact on the Outcome of Vital Pulp Therapy
NCT07261761
Pulp Inflammatory Markers and Outcome of Pulpotomy
NCT06960603
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This prospective clinical study will be conducted on 50 patients who apply to the Department of Endodontics, Faculty of Dentistry, Atatürk University, and meet the inclusion criteria. Informed consent will be obtained from all participants. A specially designed clinical assessment form will be completed for each patient to record clinical findings prior to the procedure.
Local anesthesia will be administered using 1.8 mL of 4% articaine with 1:100,000 epinephrine. Following anesthesia, the teeth will be isolated using a rubber dam. Caries removal will be performed under an operating microscope (OPMI) using a diamond bur and aerator. All infected dentin will be removed selectively until hard dentin is reached.
Pulpal bleeding will be controlled by applying a cotton pellet moistened with sterile saline into the cavity for one minute. Subsequently, pulpal fluid and blood samples will be collected using 5 mm-long sterile paper points to ensure equal sample volume per case. Each sample (one per patient) will be transferred into separate sterile Eppendorf tubes containing 500 µL of phosphate-buffered saline (PBS) and stored at -80°C until biochemical analysis. Total bleeding time will be recorded using a chronometer.
The first tube will be used for the analysis of mediators including RANTES (CCL5), MCP-1, TNF-α, TGF-β, IL-1β, TIMP-1, MMP-12, and MMP-1. The second tube will be used to measure MDA, SDA, TAS, and TOS levels.
After sample collection, the exposed pulp will be disinfected with a cotton pellet soaked in 2.5% sodium hypochlorite for 30 seconds. The cavity will then be rinsed with sterile saline and dried. The exposed pulp will be capped with Mineral Trioxide Aggregate (MTA) according to the manufacturer's instructions, and permanent restoration of the tooth will be completed.
Patients will be recalled for follow-up evaluations at 3, 6, and 12 months, during which pulpal vitality will be assessed. A correlation will be established between biomarker levels and clinical success of the vital pulp therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
reversible pulpitis
Patients diagnosed with reversible pulpitis and treated accordingly
Vital pulp therapy
Vital pulp therapy was performed using a calcium silicate-based material after caries removal and coronal pulp exposure. Hemostasis was achieved using sodium hypochlorite before placing the material. Permanent restoration was completed in the same session. Pulpal fluid samples were collected before the intervention to assess biomarker levels. The relationship between biomarker expression and the clinical success or longevity of the treated teeth was evaluated over time
Irreversible Pulpitis
Patients diagnosed with irreversible pulpitis and treated accordingly
Vital pulp therapy
Vital pulp therapy was performed using a calcium silicate-based material after caries removal and coronal pulp exposure. Hemostasis was achieved using sodium hypochlorite before placing the material. Permanent restoration was completed in the same session. Pulpal fluid samples were collected before the intervention to assess biomarker levels. The relationship between biomarker expression and the clinical success or longevity of the treated teeth was evaluated over time
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vital pulp therapy
Vital pulp therapy was performed using a calcium silicate-based material after caries removal and coronal pulp exposure. Hemostasis was achieved using sodium hypochlorite before placing the material. Permanent restoration was completed in the same session. Pulpal fluid samples were collected before the intervention to assess biomarker levels. The relationship between biomarker expression and the clinical success or longevity of the treated teeth was evaluated over time
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed with irreversible pulpitis but without apical radiolucency
* Teeth showing a normal response to cold testing (carbon dioxide snow)
* Teeth with irreversible pulpitis demonstrating prolonged response to cold testing
* Teeth with no sensitivity to percussion or chewing
* In teeth with exposed pulp tissue, bleeding time less than 5 minutes
* In irreversible pulpitis cases, bleeding time less than 10 minutes
* No widening of the periodontal ligament space (periapical index \[PAI\] ≤ 2)
* Radiographic evidence of deep dentinal caries
Exclusion Criteria
* Presence of apical radiolucency (PAI \> 2)
* Condensed apical periodontitis
* Internal or external root resorption
* History of dental trauma
* Longitudinal root fracture
* Presence of periodontal-endodontic lesions on the day of treatment
* Functional loss (e.g., Grade 3 tooth mobility)
* Swelling associated with the treated tooth
* Teeth that cannot be treated under rubber dam isolation
* Teeth from which less than 2.5 mL of pulpal blood can be collected
* Immunocompromised individuals
* Pregnant women at the time of treatment
* Use of antibiotics, bisphosphonates, or statins within 4 weeks prior to treatment
16 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ertuğrul karataş
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ertuğrul karataş
Associate Professor of Endodontics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ataturk University, Faculty of Dentistry, Department of Endodontics
Erzurum, Erzurum, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Iaculli F, Rodriguez-Lozano FJ, Briseno-Marroquin B, Wolf TG, Spagnuolo G, Rengo S. Vital Pulp Therapy of Permanent Teeth with Reversible or Irreversible Pulpitis: An Overview of the Literature. J Clin Med. 2022 Jul 11;11(14):4016. doi: 10.3390/jcm11144016.
Asgary S, Nosrat A. Vital Pulp Therapy: Evidence-Based Techniques and Outcomes. Iran Endod J. 2025;20(1):e2. doi: 10.22037/iej.v20i1.47141. Epub 2025 Jan 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NO-FUNDING-TRIAL-2025
Identifier Type: OTHER
Identifier Source: secondary_id
B.30.2.ATA.0.01.00/535
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.